VXRT - Got $3000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a Bargain
A coronavirus vaccine would arguably save countless lives and help economies around the world recover from a recession through herd immunity. As a result, everyone in the investment world is talking about biotechs that are scrambling to develop a vaccine against SARS-CoV-2, the coronavirus that causes COVID-19.
One advantage emerging coronavirus stocks have over established players is their market cap. While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks. Let's look at the four rising stars in the coronavirus vaccine race, and why investing $3,000 in any combination of them is a good idea.
Image source: Getty Images.